Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | COMT | P21964 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287304 | 0.84 | HCAR2 (0.43) | KDM5AHCAR2DRD2DRD4DRD3 | |
| SCHEMBL287605 | 0.84 | KMT2A (0.41) | HCAR2EPHX2 | |
| SCHEMBL660695 | 0.83 | HCAR2 (0.37) | KDM5AHCAR2DRD2DRD4DRD3 | |
| SCHEMBL287837 | 0.78 | CNR1 (0.40) | EPHX2 | |
| SCHEMBL287412 | 0.78 | COMT (0.41) | HCAR2DRD2DRD4DRD3ITK | |
| SCHEMBL27854956 | 0.75 | RIPK1 (0.38) | KDM5AHCAR2DRD2DRD4DRD3 | |
| SCHEMBL661116 | 0.74 | POLB (0.38) | KDM5AGRIN2B | |
| SCHEMBL298161 | 0.71 | BRS3 (0.38) | GRIN2B | |
| SCHEMBL27854968 | 0.71 | COMT (0.35) | HCAR2DRD2DRD4DRD3ITK | |
| SCHEMBL27871671 | 0.70 | HCAR2 (0.39) | KDM5AHCAR2DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459175-A | Piperidine derivatives for the treatment of diabetes | TORRENT PHARMACEUTICALS LTD | 2012-05-16 | — | — | CN | claimed |
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | claimed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | claimed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | claimed |
| CN-102459175-A | Piperidine derivatives for the treatment of diabetes | TORRENT PHARMACEUTICALS LTD | 2012-05-16 | — | — | CN | disclosed |
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | KDM5A 2197/4885HCAR2 223/4885MAPK8 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.